These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 29528251)

  • 21. Pharmacokinetics and Safety of Tedizolid after Single and Multiple Intravenous/Oral Sequential Administrations in Healthy Chinese Subjects.
    Chen R; Shen K; Chang X; Tanaka T; Li L; Hu P
    Clin Ther; 2016 Aug; 38(8):1869-79. PubMed ID: 27461846
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetic drug evaluation of tedizolid for the treatment of skin infections.
    McBride D; Krekel T; Hsueh K; Durkin MJ
    Expert Opin Drug Metab Toxicol; 2017 Mar; 13(3):331-337. PubMed ID: 28140693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of tedizolid in a patient with linezolid-induced neutropenia: A case report.
    Kobayashi S; Kase M; Matsubara M; Kitaoka A; Yasu T
    Int J Clin Pharmacol Ther; 2021 Sep; 59(9):627-629. PubMed ID: 34190685
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.
    Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tedizolid for treatment of acute bacterial skin and skin structure infections.
    Hui Y; Xiaoju L
    Expert Rev Anti Infect Ther; 2015; 13(9):1051-60. PubMed ID: 26211946
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.
    Carena AA; Stryjewski ME
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):577-592. PubMed ID: 32449440
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Single- and multiple-dose pharmacokinetics and absolute bioavailability of tedizolid.
    Flanagan S; Fang E; Muñoz KA; Minassian SL; Prokocimer PG
    Pharmacotherapy; 2014 Sep; 34(9):891-900. PubMed ID: 24989138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: efficacy summary.
    O'Riordan W; Green S; Mehra P; De Anda C; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S43-50. PubMed ID: 24343832
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Phase 3, Randomized, Double-Blind Study Comparing Tedizolid Phosphate and Linezolid for Treatment of Ventilated Gram-Positive Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia.
    Wunderink RG; Roquilly A; Croce M; Rodriguez Gonzalez D; Fujimi S; Butterton JR; Broyde N; Popejoy MW; Kim JY; De Anda C
    Clin Infect Dis; 2021 Aug; 73(3):e710-e718. PubMed ID: 33720350
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial.
    O'Riordan W; Cardenas C; Shin E; Sirbu A; Garrity-Ryan L; Das AF; Eckburg PB; Manley A; Steenbergen JN; Tzanis E; McGovern PC; Loh E;
    Lancet Infect Dis; 2019 Oct; 19(10):1080-1090. PubMed ID: 31474458
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tedizolid phosphate for the management of acute bacterial skin and skin structure infections: safety summary.
    Das D; Tulkens PM; Mehra P; Fang E; Prokocimer P
    Clin Infect Dis; 2014 Jan; 58 Suppl 1():S51-7. PubMed ID: 24343833
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lack of neuropathological changes in rats administered tedizolid phosphate for nine months.
    Schlosser MJ; Hosako H; Radovsky A; Butt MT; Draganov D; Vija J; Oleson F
    Antimicrob Agents Chemother; 2015 Jan; 59(1):475-81. PubMed ID: 25385101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
    Rybak JM; Marx K; Martin CA
    Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tedizolid population pharmacokinetics, exposure response, and target attainment.
    Flanagan S; Passarell J; Lu Q; Fiedler-Kelly J; Ludwig E; Prokocimer P
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6462-70. PubMed ID: 25136028
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and safety of tedizolid for the treatment of ventilated gram-positive hospital-acquired or ventilator-associated bacterial pneumonia in Japanese patients: Results from a subgroup analysis of a phase 3, randomized, double-blind study comparing tedizolid and linezolid.
    Mikamo H; Nagashima M; Kusachi S; Fujimi S; Oshima N; De Anda C; Takase A
    J Infect Chemother; 2022 Sep; 28(9):1235-1241. PubMed ID: 35718656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of tedizolid against methicillin-resistant Staphylococcus aureus and Peptostreptococcus anaerobius in thigh mixed-infection mouse model.
    Yamagishi Y; Mikamo H; Kato H; Nishiyama N; Asai N; Koizumi Y; Sakanashi D; Suematsu H; Matsuura K; Hagihara M
    J Infect Chemother; 2017 Jun; 23(6):368-373. PubMed ID: 28343752
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of therapeutic and supratherapeutic doses of oral tedizolid phosphate on cardiac repolarisation in healthy volunteers: a randomised controlled study.
    Flanagan S; Litwin J; Fang E; Prokocimer P
    Int J Antimicrob Agents; 2016 Jul; 48(1):33-40. PubMed ID: 27342387
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Characterization of Neurologic and Ophthalmologic Safety of Oral Administration of Tedizolid for Up to 21 Days in Healthy Volunteers.
    Fang E; Muñoz KA; Prokocimer P
    Am J Ther; 2017; 24(2):e227-e233. PubMed ID: 27941424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Radiolabeled Tedizolid Phosphate Liposomes for Topical Application: Design, Characterization, and Evaluation of Cellular Binding Capacity.
    Karpuz M; Atlihan-Gundogdu E; Demir ES; Senyigit Z
    AAPS PharmSciTech; 2021 Feb; 22(2):62. PubMed ID: 33528714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.